BR112021020141A2 - Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva - Google Patents

Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva

Info

Publication number
BR112021020141A2
BR112021020141A2 BR112021020141A BR112021020141A BR112021020141A2 BR 112021020141 A2 BR112021020141 A2 BR 112021020141A2 BR 112021020141 A BR112021020141 A BR 112021020141A BR 112021020141 A BR112021020141 A BR 112021020141A BR 112021020141 A2 BR112021020141 A2 BR 112021020141A2
Authority
BR
Brazil
Prior art keywords
hearing loss
chir99021
combination
valproic acid
treating hearing
Prior art date
Application number
BR112021020141A
Other languages
English (en)
Inventor
Ashley Hinton
Carl Lebel
Christopher Loose
Jenna Herby
Moraye Bear
Will Mclean
Original Assignee
Frequency Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frequency Therapeutics Inc filed Critical Frequency Therapeutics Inc
Publication of BR112021020141A2 publication Critical patent/BR112021020141A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

combinação de chir99021 e ácido valpróico para tratamento de perda auditiva. são fornecidos neste documento compostos para uso no tratamento de perda auditiva neurossensorial em um paciente humano, por exemplo, agente(s) de regeneração de célula ciliada para uso no tratamento de perda auditiva neurossensorial em um ser humano. também são fornecidos métodos de tratamento da perda auditiva neurossensorial em um ser humano por meio da administração de determinados compostos, por exemplo, agente(s) de regeneração de célula ciliada.
BR112021020141A 2019-04-08 2020-04-08 Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva BR112021020141A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962831170P 2019-04-08 2019-04-08
US201962831169P 2019-04-08 2019-04-08
US201962831167P 2019-04-08 2019-04-08
PCT/US2020/027316 WO2020210388A1 (en) 2019-04-08 2020-04-08 Combination of chir99021 and valproic acid for treating hearing loss

Publications (1)

Publication Number Publication Date
BR112021020141A2 true BR112021020141A2 (pt) 2021-12-21

Family

ID=70476486

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020141A BR112021020141A2 (pt) 2019-04-08 2020-04-08 Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva

Country Status (14)

Country Link
US (1) US20220175776A1 (pt)
EP (1) EP3952854A1 (pt)
JP (1) JP2022527391A (pt)
KR (1) KR20220007050A (pt)
CN (1) CN114340611A (pt)
AU (1) AU2020271067A1 (pt)
BR (1) BR112021020141A2 (pt)
CA (1) CA3136424A1 (pt)
IL (1) IL287094A (pt)
MA (1) MA55611A (pt)
MX (1) MX2021012258A (pt)
SG (1) SG11202111191YA (pt)
TW (1) TW202103692A (pt)
WO (1) WO2020210388A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022112511A1 (en) * 2020-11-26 2022-06-02 Alain Moussy Pharmaceutical composition for treatment of inner ear disorders through local administration in the tympanic area

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
US8870826B2 (en) 2004-05-24 2014-10-28 Auris Medical Llc Combined otic aspirator and medication dispenser
EP2254572B1 (en) 2008-02-07 2013-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
WO2012103012A1 (en) 2011-01-24 2012-08-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for generating inner ear cells in vitro
AR087107A1 (es) 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
EP2606884A1 (en) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
JP6138928B2 (ja) 2012-06-01 2017-05-31 ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー．ファウ．（エフエルイー） 医薬に使用されるｎｏｔｃｈシグナル伝達経路及び分泌の阻害物質
EP3970725A1 (en) 2012-09-07 2022-03-23 Massachusetts Eye & Ear Infirmary A gamma secretase inhibitor for treating hearing loss
JP2015534554A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物
EP2897938B1 (en) 2012-09-21 2017-03-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
EP2897941B1 (en) 2012-09-21 2016-09-07 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
US9133139B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
CN104822665A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物
JP2015534553A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換１，５−ベンゾジアゼピノン化合物
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
US20170304369A1 (en) 2014-10-08 2017-10-26 Agency For Science, Technology And Research Methods of differentiating stem cells into liver cell lineages
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
CA3014659A1 (en) 2016-03-02 2017-09-08 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using gsk-3-alpha inhibitors
EP3475279B1 (en) 2016-06-27 2021-07-14 F. Hoffmann-La Roche AG Triazolopyridines as gamma-secretase modulators
EP3481829B1 (en) 2016-07-08 2021-04-07 H. Hoffnabb-La Roche Ag Fused pyrimidine derivatives
JP6980751B2 (ja) 2016-07-14 2021-12-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 縮合ピリミジン誘導体
AR109829A1 (es) 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
CN109476670B (zh) 2016-10-04 2022-06-28 豪夫迈·罗氏有限公司 二环杂芳基衍生物
WO2018087018A1 (en) 2016-11-08 2018-05-17 F. Hoffmann-La Roche Ag Phenoxytriazoles
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法
EP3562483A4 (en) 2016-12-20 2020-06-03 Oligomerix, Inc. INNOVATIVE BENZOFURANE, BENZOTHIOPHENE AND INDOLANALOGA FOR INHIBITING THE FORMATION OF TAU OLIGOMERS AND THE USE THEREOF
EP4252856A3 (en) 2016-12-20 2024-01-24 Oligomerix, Inc. Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
US10383881B2 (en) 2016-12-30 2019-08-20 Frequency Therapeutics, Inc. 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
BR112019013388A2 (pt) 2016-12-30 2020-03-03 Frequency Therapeutics, Inc. Compostos de 1h-pirrol-2,5-diona e métodos de uso dos mesmos para induzir a autorrenovação de células de suporte tronco/progenitoras
US20180271837A1 (en) 2017-03-24 2018-09-27 Novartis Ag Isoxazole carboxamide compounds and uses thereof
WO2020037323A1 (en) * 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
WO2020037325A1 (en) * 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating pi3k
TW202034900A (zh) * 2018-10-02 2020-10-01 美商頻率醫療公司 有關耳用治療劑之醫藥組成物及方法

Also Published As

Publication number Publication date
SG11202111191YA (en) 2021-11-29
US20220175776A1 (en) 2022-06-09
MA55611A (fr) 2022-02-16
WO2020210388A1 (en) 2020-10-15
EP3952854A1 (en) 2022-02-16
TW202103692A (zh) 2021-02-01
IL287094A (en) 2021-12-01
CN114340611A (zh) 2022-04-12
CA3136424A1 (en) 2020-10-15
KR20220007050A (ko) 2022-01-18
JP2022527391A (ja) 2022-06-01
MX2021012258A (es) 2022-01-04
AU2020271067A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2020012028A (es) Metodos y composiciones para tratar el cancer.
CY1118105T1 (el) Αγγειογενεση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα
BR112017023380A2 (pt) sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo.
CO2020001960A2 (es) Formulaciones de anticuerpos anti-c5 de alta concentración
MX2020005547A (es) Moduladores de la actividad del complemento.
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
MX2020012018A (es) Composiciones para el tratamiento de condiciones de la piel.
BR112017015387A2 (pt) composição em gel tópica, método de tratamento de uma infecção da pele, composição em gel oftálmica, e, método de tratamento de uma afecção infecciosa do olho ou pálpebra
MX2020000713A (es) Metodos de aferesis y sus usos.
BR112021017878A2 (pt) Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação
MX2020011817A (es) Metodos para tratar el linfoma.
MX2022004056A (es) Composicion novedosa para el cuidado de la piel.
MX2020006944A (es) Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer.
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов
MX2022004055A (es) Composicion novedosa para el cuidado de la piel.
BR112021020141A2 (pt) Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
MY196026A (en) Stem Cell Conditioned Media for Clinical and Cosmetic Applications
WO2021091938A8 (en) Cochlear outer hair cell promoters and uses thereof
BR112021010804A2 (pt) Métodos para expansão seletiva in vivo de populações de células t gama delta e composições das mesmas
BR112021021676A2 (pt) Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal
BR112021018858A2 (pt) Chiauranibe para tratamento de câncer de pulmão de células pequenas
GEP20227384B (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
EA202192751A1 (ru) Композиции и способы для лечения потери слуха

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]